Welcome to today’s FDA/CDRH Webinar

Thank you for your patience while additional time is provided for participants to join the call.

Please connect to the audio portion of the webinar now:
US Callers Dial: 888-945-5893
International Callers Dial: 1-212-547-0152
Conference Number: PWXW9410351
Passcode:1273630
Acceptance Review for De Novo Classification Requests

Sergio M. de del Castillo
De Novo Program Lead
Division of Submission Support
Office of Regulatory Programs

Center for Devices and Radiological Health

September 18, 2019
Agenda

• Objectives
• Background
• Summary of Final Guidance
• Transition Period for Final Guidance
• Resources
• Questions
Objectives

After this training, you should be able to:

• Understand the acceptance review policy and process for original De Novo requests

• Identify the content elements necessary for acceptance of DeNovo requests

• Identify the actions the FDA may take during the acceptance review
Definitions

• **RTA**: Refuse to Accept

• **De Novo RTA Guidance**: [Acceptance Review for De Novo Classification Requests](#)

• **De Novo Actions/Clock Guidance**: [FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals](#)

• **De Novo User Fees Guidance**: [User Fees and Refunds for De Novo Classification Requests](#)
With the enactment of the Medical Device User Fee Amendments of 2017 (MDUFA IV), the U.S. Food and Drug Administration (FDA) agreed to performance goals based on the timeliness of reviews of De Novo classification requests.

To facilitate a more efficient and timely review process, the FDA committed to developing draft and final guidance that includes a “submission checklist.”

The FDA issued the draft guidance “Acceptance Review for De Novo Classification Requests” on October 30, 2017.
Summary of De Novo RTA Guidance

Goal: Ensure original De Novo request is acceptable for substantive review

- Identifies content necessary for acceptance of De Novo requests
- Facilitates efficient and timely review
- Modeled after RTA policies for 510(k) and PMA
- Honors MDUFA IV commitment ("submission checklist")
- Only a few minor changes compared to draft guidance
## Summary of De Novo RTA Guidance

<table>
<thead>
<tr>
<th>Appendix A</th>
<th>Appendix B</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acceptance Checklist</strong></td>
<td><strong>Recommended Content Checklist</strong></td>
</tr>
<tr>
<td>Necessary for acceptance</td>
<td>Optional</td>
</tr>
<tr>
<td><strong>Examples:</strong></td>
<td><strong>Examples:</strong></td>
</tr>
<tr>
<td>Intended use</td>
<td>Prior submissions</td>
</tr>
<tr>
<td>Device description</td>
<td>Classification summary (eligibility)</td>
</tr>
<tr>
<td>Proposed special controls (if</td>
<td>Device labeling</td>
</tr>
<tr>
<td>recommending class II)</td>
<td></td>
</tr>
</tbody>
</table>


The Recommended Content Checklist will **NOT** be used to conduct RTA reviews.
Summary of Updates to Other Guidances

**De Novo Actions/Clock Guidance**
- Identifies actions the FDA and requester may take during RTA review
- Explains how these actions impact review clock

**De Novo User Fees Guidance**
- Identifies criteria for requesting user fee refund if De Novo is not accepted for review
- Explains how to request a user fee refund
Overview of De Novo RTA Policy and Process

• Determine if De Novo is administratively complete based only on Acceptance Checklist (Appendix A)

• Not intended to be a substantive review

• Intend to complete RTA review within 15 calendar days of receiving original De Novo

• De Novo is considered accepted if RTA review is not completed within 15 calendar days
Overview of De Novo RTA Policy and Process

**Refuse to Accept (RTA) Decision**

- De Novo is incomplete; will not begin substantive review.
- The FDA will email requester that De Novo is not accepted.
- The FDA will identify those items that are missing.
- De Novo is placed on hold until missing elements are provided.
- Review clock resets to Day 0.
- The Requester has 180 days to provide missing elements.
Overview of De Novo RTA Policy and Process

**Accepted Decision**

- De Novo is administratively complete; substantive review begins.

- The FDA will email requester that De Novo is accepted.

- Review clock continues from date of original submission (or date of submission of missing elements).
De Novo RTA Guidance – Transition Plan

- **September 8, 2019**
  - Publication of final De Novo RTA Guidance
  - Updates to De Novo Actions/Clock and De Novo User Fees Guidances

- **September 8 through November 7**
  - 60-day transition period
  - FDA intends to accept all original De Novo requests
  - No formal RTA review will be conducted

- **November 8, 2019**
  - Formal RTA reviews will begin
  - Applies to new original De Novos received on or after this date
Resources

- CDRH Device Advice – De Novo
- Acceptance Review for De Novo Classification Requests
- FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals
- User Fees and Refunds for De Novo Classification Requests
- Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions
Questions?

Division of Industry and Consumer Education:
DICE@fda.hhs.gov

Slide Presentation, Transcript and Webinar Recording will be available at:
http://www.fda.gov/training/cdrhlearn
Under Heading: “How to Study and Market Your Device”; Subheading: De Novo

Please complete a short survey about your FDA CDRH webinar experience. The survey can be found at www.fda.gov/CDRHWebinar immediately following the conclusion of the live webinar.